| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 48 Number 5
Volume 48 Number 4
Volume 48 Number 3
Volume 48 Number 2
Volume 48S Number 1
Volume 48 Number 1
Earlier issues
Volume 48 Number 2 Volume 48 Number 3 Volume 48 Number 4

previous article next article

Research articles

ScienceAsia 48 (2022): 359-366 |doi: 10.2306/scienceasia1513-1874.2022.054


DUB3 contributes to colorectal cancer cell migration and angiogenesis via NF-κB/HIF-1α


Dezhen Yanga, Yang Huia, Shaokai Baib, Weijian Liangb, Junming Houa, Jing Jiangc,*

 
ABSTRACT:     Colorectal cancer (CRC) is a common malignancy with poor prognosis. This study aimed to explore the role of deubiquitinase 3 (DUB3) in CRC cell migration and angiogenesis as well as its molecular mechanism. HCT116 cells were transfected with DUB3 or EZH2 siRNA, or vectors overexpressing EZH2/HIF-1?. CCK8 and colony formation assay were used to assess cell proliferation; wound healing assay and Transwell assay were performed to determine cell migration and invasion; angiogenesis in CRC was detected using tube formation assay; WB was used to measure the protein levels of DUB3, EZH2, p65, p-p65, and HIF-1?. DUB3 downregulation inhibited proliferation, migration, invasion, and angiogenesis in CRC cells. Moreover, DUB3 could positively regulate NF-?B/HIF-1? pathway through EZH2. Overexpression of HIF-1? reversed the effects of DUB3 knockdown on CRC cell proliferation, migration, invasion, and angiogenesis. DUB3 contributes to CRC metastasis and angiogenesis by regulating NF-?B/HIF-1? pathway via EZH2, which may indicate a novel insight for the pathogenesis of CRC.

Download PDF

21 Downloads 476 Views


a Department of Surgical Oncology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Shaanxi 712000 China
b First Department of Clinical Medicine, Shaanxi University of Chinese Medicine, Shaanxi 712046 China
c Fourth ward of Tumor Hospital, Affiliated Hospital of Shaanxi University of Chinese Medicine, Shaanxi 712000 China

* Corresponding author, E-mail: jiangjing83_dr@163.com

Received 9 Oct 2021, Accepted 11 Jan 2022